The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial
Youssef et al., Critical Care Medicine, doi:10.1097/CCM.0000000000005660
https://c19early.org/youssef.html